Sodium Selenate as a Disease-Modifying Treatment for Mild to Moderate Alzheimer’s Disease: An Open-Label Extension Study

    December 2021 in “ BMJ neurology open
    Lucy Vivash, Charles B Malpas, Christopher M. Hovens, Amy Brodtmann, Steven Collins, Stephen Macfarlane, Dennis Velakoulis, Terence J. O’Brien
    Image
    Studysummary This study on Alzheimer's patients found that chronic sodium selenate treatment (up to 23 months) was safe and well-tolerated, with most adverse events being mild, and suggested potential slowing of cognitive decline, though confirmation requires further controlled studies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →